Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(4):308-312
DOI: 10.5428/pcar20180420
Clinical distribution and drug resistance of the multidrug-resistant Acinetobacter baumannii in the Third People’s Hospital of Kunming City from 2015 to 2017
1. PENG JiangLi(Department of Pharmacy, Third People’s Hospital of Kunming City,Kunming 650041,China pengjiangli110@163.com)
2. CHEN Jie(Department of Pharmacy, Third People’s Hospital of Kunming City,Kunming 650041,China )
3. LUO Ji(Department of Pharmacy, Third People’s Hospital of Kunming City,Kunming 650041,China )
4. YU MingLi(Department of Pharmacy, Third People’s Hospital of Kunming City,Kunming 650041,China 13529017398@163.com)
5. LIU MengXing(Department of Pharmacy, Third People’s Hospital of Kunming City,Kunming 650041,China )
6. WANG JunLong(Department of Pharmacy, Third People’s Hospital of Kunming City,Kunming 650041,China )
ABSTRACT  Objective: To monitor clinical distribution and drug resistance of the multidrug-resistant Acinetobacter baumannii(MDR-AB) in the Third People’s Hospital of Kunming City,so as to provide evidence for rational use of antibacterials and control of infection by A. baumannii.Methods: MDR-AB strains were collected retrospectively from 2015 to 2017 in our hospital.The strain numbers, department distribution,specimen sources and drug resistance changes of MDR-AB to 17 kinds of antibacterials were analyzed.Results: Totally, 140 MDR-AB strains were detected in our hospital from 2015 to 2017.The proportions of MDR-AB to A. baumannii and to total pathogens per year displayed an increasing trend.MDR-AB mainly distributed in ICU (60.0%),followed by the Second Department of Tuberculosis(10.0%) and Department of Respiratory Medicine (7.9%).The distribution of MDR-AB in ICU decreased year by year, while the distribution of MDR-AB in the Second Department of Tuberculosis and Department of Respiratory Medicine increased year by year.The main sources of MDR-AB specimens were sputum(70.7%) and bronchial brushing(21.4%).The resistance rate of MDR-AB to amikacin was the lowest from 2015 to 2017,and the overall resistance rate was 50.0%.The overall resistance rates of MDR-AB to ampicillin,amoxillin/clavulanate potassium and cefazolin sodium were above 93.6%.The resistance rates of MDR-AB to amikacin,cefazolin sodium,imipenem/simvastatin sodium,piperacillin sodium and tetracycline increased year by year,but on the whole, no statistical significance could be seen (P>0.05).The resistance of MDR-AB to the other 12 antibacterials also increased year by year,and with statistical significance(P<0.05).Conclusion: The separation rate and drug resistance rate of MDR-AB increased year by year from 2015 to 2017 in our hospital.More effective infection control measures should be taken by the hospital, dynamic monitoring of MDR-AB,disinfection and isolation should be strengthened,and broad-spectrum antibacterials should be used rationally, so as to prevent and reduce the growth and transmission of MDR-AB in the hospital.
Welcome to PCAR! You are the number 67 reader of this article!
Please cite this article as:
PENG JiangLi,CHEN Jie,LUO Ji,YU MingLi,LIU MengXing,WANG JunLong,. Clinical distribution and drug resistance of the multidrug-resistant Acinetobacter baumannii in the Third People’s Hospital of Kunming City from 2015 to 2017[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 308-312.
References:
1. CHEN HaoJun, LI CongRong. Research updates on the mechanisms of tigecycline resistance in Acinetobacter baumannii[J].Chin J Infect Chemother,2017, 17(3):336-340.In Chinese with English title.
2. ZHANG Hui,ZHANG XiaoJiang,XU YingChun,et al.Resistance profile of Acinetobacter isolates in hospitals across China:results from CHINET Antimicrobial Resistance Surveillance Program 2005-2014[J]. Chin J Infect Chemother,2016,16(4):429-436.In Chinese with English abstract.
3. CHEN BaiYi,HE LiXian,HU BiJie,et al.Expert consensus on the prevention,diagnosis and treatment of infection by Acinetobacter baumannii in China[J].Natl Med J China,2012,92(2):76-85.In Chinese.
4. ZHANG YuQiong,GAO JingJing,LU WenXiang,et al.Clinical distribution, drug resistance and drug resistance genes of Acinetobacter baumannii in our hospital from 2014 to 2017[J].China Pharmacy,2018,29(6):794-799.In Chinese with English abstract.
5. MENG ZhiJun.Clinical distribution and drug resistance analysis of 1060 strains of carbapenem-resistant Acinetobacter baumannii[J].Chin Remed Clin,2017,17(11):1609-1611.In Chinese.
6. SONG XiaoPing,CHEN JiaHong,ZHAI JunQing,et al.A study of antibiotics resistance and carbapenemase genotype of Acinetobacter baumannii in intensive care unit of Qingdao[J].Chin J Lab Med,2017,40(3):216-220.In Chinese with English abstract.
7. SUN ShiPeng,KUANG NanYue,QI XinWen.Multiple drug resistant Acinetobacter baumannii infection associated risk factors and drug resistance analysis[J].Chin J Clin Ration Drug Use,2018,11(1A):7-11.In Chinese with English abstract.
8. HE Le,XIAO ShuZhen,HAN LiZhong,et al.The correlation between drug resistance of Acinetobacter baumannii and antibacterial use density[J].Pharm Care Res,2014,14(5):360-363.In Chinese with English abstract.
9. LIANG PeiPei,LU HongZhou.Prevention,control and management patterns of hospital infections caused by multi-drug resistant bacteria[J].J Clin Intern Med,2018,35(3):158-160.In Chinese.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口